Adient plc (ADNT) Stock Price & Analysis
Adient plc (ADNT) closed at USD 18.18 on Thursday, October 15, 2026, up 3.47% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.57; the Oct 15, 2026 session ranged USD 17.77–18.34 on volume of 907,960 shares. Market capitalization is $1.43B, with a 52-week range of USD 16.51–27.32 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ADNT.md
Key facts (ADNT)
- 1 of 80 tracked superinvestors hold ADNT (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.33 on a 1–5 scale) (12 analysts), mean target USD 28.64 (range 21–64).
- Total return with dividends: 1Y -21.2% vs S&P 500 +18.1%; 5Y -60.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.64, revenue estimate $3.60B.
Superinvestors (SEC 13F-HR, Q2 2026) (ADNT)
1 of 80 tracked investors hold ADNT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 0.20% | $69.3M | Added +3.7% |
Analysts (ADNT)
Consensus Buy (mean 2.33 on a 1–5 scale), 12 analysts; mean target USD 28.64 (low 21, high 64).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Barclays | Target lowered | Equal-Weight | $25 → $22 |
| 2026-10-07 | UBS | Target lowered | Buy | $29 → $23 |
| 2026-09-15 | JP Morgan | Upgrade | Neutral → Overweight | $28 → $25 |
| 2026-08-18 | Morgan Stanley | Target lowered | Equal-Weight | $22 → $21 |
| 2026-08-11 | Citigroup | Target lowered | Buy | $33 → $29 |
| 2026-08-10 | JP Morgan | Target raised | Neutral | $26 → $28 |
| 2026-08-10 | Barclays | Target lowered | Equal-Weight | $29 → $25 |
| 2026-08-06 | UBS | Target lowered | Buy | $34 → $29 |
| 2026-07-20 | Stifel | Target lowered | Buy | $28 → $26 |
| 2026-07-09 | UBS | Target raised | Buy | $33 → $34 |
| 2026-07-06 | Deutsche Bank | Target lowered | Buy | $31 → $29 |
| 2026-06-25 | Wells Fargo | Target raised | Overweight | $28 → $32 |
Total return (dividends reinvested) (ADNT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -21.2% | -60.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -21.3% | -16.9% |
| Volatility (annualized) | 51.8% | 45.5% |
| Max drawdown | -37.8% (Feb 2026→Sep 2026) | -79.3% (Jan 2022→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 18.18 |
|---|---|
| Change | ▲ 3.47% (up) |
| Previous Close | USD 17.57 |
| Open | USD 17.7 |
| Day Range | USD 17.77 – 18.34 |
| 52-Week Range | USD 16.51 – 27.32 |
| Volume | 907,960 shares |
| Market Cap | $1.43B |
| Exchange | NYQ |
Technical Analysis (ADNT)
Nexqual's technical model rates ADNT "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52.65 (neutral) |
| vs SMA50 | Below (USD 18.48) |
| MACD | -0.22 (negative) |
Analyst Ratings (ADNT)
Wall Street analysts rate ADNT "Buy" based on 12 analysts, with a mean price target of USD 28.64 (range USD 21–64), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 28.64 |
| High Target | USD 64 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 8 / 3 / 1 |
Earnings (ADNT)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.64 |
| Revenue Estimate | $3.60B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.48 vs est 0.57 ▼ miss |
| 2026-03-31 | USD 0.52 vs est 0.44 ▲ beat |
| 2025-12-31 | USD 0.35 vs est 0.19 ▲ beat |
| 2025-09-30 | USD 0.52 vs est 0.56 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (ADNT)
| Total Revenue | $15.13B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.00% |
| Gross Margin | +6.59% |
| Operating Margin | +2.49% |
| Profit Margin | +0.32% |
| ROE | +5.79% |
| Debt / Equity | 1.27 |
| Current Ratio | 1.1 |
| Total Cash | $927.00M |
| Total Debt | $2.65B |
| Free Cash Flow (fiscal year ended Sep 2025, SEC 10-K) | $204.00M (1.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (ADNT)
Nexqual rates Adient plc's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Weak — Gross margin 7%, operating 2% |
| Balance Sheet | Mixed — $927M cash vs $2.65B debt |
| Cash Flow | Mixed — FCF $204M (FY ended Sep 2025, 10-K), slim 1.4% margin |
| Efficiency | Mixed — ROE 6%, ROA 3.1% |
Ownership (ADNT)
| Insider Ownership | +1.17% |
|---|---|
| Institutional Ownership | +101.93% |
| Shares Outstanding | 78.41M |
| Float | 75.89M |
| Short % of Float | +10.45% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (ADNT)
Adient plc is led by Jerome J. Dorlack (age 44), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | Jerome J. Dorlack (age 44) |
|---|---|
| Executive VP & CFO | Mark A. Oswald (age 58) |
| Executive Vice President of APAC | James Jian Huang (age 63) |
| Executive Vice President - Americas | James D. Conklin (age 52) |
| Executive Vice President of EMEA | David Herberg |
Major Backers & Investors (ADNT)
Notable institutional backers of Adient plc include Pzena Investment Management LLC, Shaw D.E. & Co., Inc., Hotchkis & Wiley Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pzena Investment Management LLC | 4.89% |
| Shaw D.E. & Co., Inc. | 4.02% |
| Hotchkis & Wiley Capital Management, LLC | 3.19% |
| Arrowstreet Capital, Limited Partnership | 2.91% |
| HITE Hedge Asset Management LLC | 2.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 28.24% |
| Vanguard Group | 6.53% |
| Dimensional Fund Advisors | 5.6% |
| State Street | 5.19% |
| Geode Capital | 2.62% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATMU | Atmus Filtration Technologies I | USD 43.98 | ▲ 0.5% |
| DORM | Dorman Products, Inc. | USD 123.63 | ▲ 0.24% |
| GNTX | Gentex Corporation | USD 21.11 | ▲ 1.15% |
| GTX | Garrett Motion Inc. | USD 24.45 | ▼ 5.18% |
| LKQ | LKQ Corporation | USD 22.36 | ▲ 0.81% |
| LEA | Lear Corporation | USD 121.49 | ▲ 1.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt